PCRX
Pacira BioSciences·NASDAQ
--
--(--)
--
--(--)
5.58 / 10
Netural
Fund flow is strong (7.86/10) with positive inflows across most investor sizes except large blocks. One analyst rates PCRX neutral, yielding a 100% neutral distribution. The overall sentiment is balanced, but the bullish fund activity slightly outweighs the neutral analyst view.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
0%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-26
InstitutionBarclays
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for PCRX?
- PCRX holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.58/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
